Newsroom

CANTON, Massachusetts--(BUSINESS WIRE)--Orthogon Therapeutics gab heute den Abschluss einer Folgefinanzierung in Höhe von 11 Millionen US-Dollar bekannt, womit sich das insgesamt eingeworbene Kapital auf 36 Millionen US-Dollar erhöht. Die Finanzierung ermöglicht die weitere Entwicklung des First-in-Class-Medikaments gegen das BK-Polyomavirus. BK-Virus-Infektionen sind eine der Hauptursachen für Komplikationen bei Transplantationspatienten, wobei es bislang keine zugelassenen Behandlungsmethoden...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Green Circle Decarbonize Technology Ltd. (NYSE American: GCDT) resulting from allegations that Green Circle may have issued materially misleading business information to the investing public. So what: If you purchased Green Circle securities you may be entitled to compensation without payment of any out of pocket fees or costs...

CANTON, Massachusetts--(BUSINESS WIRE)--A empresa anunciou hoje o fechamento de um financiamento adicional de US$ 11 milhões, elevando o capital total levantado para US$ 36 milhões. Esse investimento apoiará o avanço contínuo de seu medicamento pioneiro contra o poliomavírus BK. As infecções pelo BK são uma das principais causas de complicações em pacientes transplantados, e não há tratamentos aprovados para elas. A empresa é pioneira em uma terapia oral que abrange todo o espectro da infecção...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Studies will showcase the ultrasensitive structural variant-based detection of ctDNA in metastatic breast cancer and high-grade serous ovarian cancer...

SAN DIEGO--(BUSINESS WIRE)--Qualcomm Incorporated (NASDAQ: QCOM) ha anunciado hoy un dividendo trimestral en efectivo de 0,92 dólares por acción ordinaria, pagadero el día 25 de junio de 2026 a los accionistas registrados al cierre de la jornada del 4 de junio de 2026. Acerca de Qualcomm Qualcomm innova sin descanso para que la informática inteligente llegue a todas partes y sea una herramienta para que el mundo a abordar algunos de sus desafíos más importantes. Con el aval de 4 décadas de lide...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of Class A common stock of NuScale Power Corporation (NYSE: SMR) between May 13, 2025 and November 6, 2025. NuScale describes itself as a “developer of nuclear power technology.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that N...

WASHINGTON--(BUSINESS WIRE)--A new research report commissioned by the District Department of Transportation reinforces what traffic expert Amy Witherite and other safety advocates have been warning: autonomous vehicles are not yet ready for unrestricted deployment in complex urban environments in complex urban environments, and a cautious, accountability-driven approach is essential. Amy Witherite, a leading advocate for roadway safety, highlighted the report’s findings as validation of ongoin...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Elite Express Holding Inc. (NASDAQ: ETS) resulting from allegations that Elite Express may have issued materially misleading business information to the investing public. So what: If you purchased Elite Express securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has been named a 2026 Top Workplace by USA TODAY. The award is based on employee feedback collected via a confidential survey measuring workplace experience and engagement. USA TODAY Top Workplaces recognizes midsize and large organizations in the US that are exceeding national benchmarks for employee satisfaction. “We are honored to be recognized with this national award, and proud to have created an environment that fosters ingenuity, insight and integr...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer (ES-SCLC) and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases (mRAN...